Stereotaxis (NYSEAMERICAN:STXS) Stock Price Up 8.2%

Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXSGet Rating) rose 8.2% during mid-day trading on Monday . The company traded as high as $2.12 and last traded at $2.10. Approximately 206,704 shares changed hands during mid-day trading, a decline of 43% from the average daily volume of 365,550 shares. The stock had previously closed at $1.94.

Analyst Upgrades and Downgrades

STXS has been the subject of several analyst reports. Piper Sandler lowered their price objective on Stereotaxis from $8.00 to $6.00 in a research report on Tuesday, August 9th. B. Riley assumed coverage on Stereotaxis in a research note on Thursday, June 23rd. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, Aegis assumed coverage on Stereotaxis in a report on Tuesday, July 12th. They issued a “buy” rating and a $6.00 target price on the stock.

Stereotaxis Price Performance

The stock has a market capitalization of $157.06 million, a PE ratio of -8.40 and a beta of 1.70.

Institutional Trading of Stereotaxis

Institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC purchased a new stake in Stereotaxis during the 4th quarter worth $67,000. Dimensional Fund Advisors LP grew its position in Stereotaxis by 7.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 289,609 shares of the company’s stock worth $1,796,000 after purchasing an additional 20,419 shares during the last quarter. Essex Investment Management Co. LLC grew its position in Stereotaxis by 8.3% in the 4th quarter. Essex Investment Management Co. LLC now owns 264,805 shares of the company’s stock worth $1,642,000 after purchasing an additional 20,319 shares during the last quarter. GSA Capital Partners LLP grew its position in Stereotaxis by 552.4% in the 4th quarter. GSA Capital Partners LLP now owns 232,349 shares of the company’s stock worth $1,441,000 after purchasing an additional 196,733 shares during the last quarter. Finally, Kent Lake Capital LLC bought a new position in shares of Stereotaxis in the fourth quarter valued at approximately $2,170,000. 48.74% of the stock is owned by hedge funds and other institutional investors.

About Stereotaxis

(Get Rating)

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.

Further Reading

Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.